Close
Close
Treatment News

Company strengthens organization for further growth

2.0
2.0 from 11 votes
Friday, December 06, 2013

Learn more about:

Access Programs

Leiden, the Netherlands, – to-BBB, the brain drug development company, appoints Carlos de Sousa, MD, MBA, as Chief Business Officer perJanuary 1st, 2014. Dr. de Sousa joins to-BBB after a career in Business Development in several major pharmaceutical and biotech companies. His most recent position was at Takeda/Nycomed, where he was Vice President and Head of Commercial Licensing. While to-BBB is in Phase IIa with 2B3-101 for brain cancer, moving to Phase I with 2B3-201 for MS, and expanding its pipeline, the insight and network of Dr. de Sousa will be instrumental to involve partners in to-BBB’s drug development strategy.

“Carlos joins us at a pivotal moment for the company,” says Willem van Weperen, CEO of to-BBB. “With two products that can move into pivotal trials in a year from now and a further pipeline of brain disease products, to-BBB is making large value steps. We look forward to have such an experienced Chief Business Officer on board to support our growth with a strategy that includes partnering with pharma companies.”

“I am delighted to join to-BBB at such an exciting time for the company. I look forward to contribute to their further growth by driving the partnering efforts for a very promising pipeline, and ultimately bring new medications to patients in need of innovative solutions to such serious medical conditions,” says Dr. Carlos de Sousa.

Recently, to-BBB completed a Phase I clinical trial in patients with brain cancer with its lead product 2B3-101, demonstrating safety and anti-tumor activity at clinically relevant dosages. The product has now moved into Phase IIa in Europe and US, treating patients with brain metastases from solid tumors, as well as patients with malignant gliomas. to-BBB’s second product 2B3-201 addresses acute relapses of Multiple Sclerosis, as well as other neuroinflammatory diseases. This product is expected to start Phase I at the end of this year followed by a relatively short route towards marketing authorization.

Dr. Carlos de Sousa is a Medical Doctor and Research Fellow from the University of Lisbon and holds an EMBA from the NYU Stern School of Business. He started his pharmaceutical industry career in medical positions at Duphar and Pfizer. Carlos obtained his international Business Development experience at Pfizer, Novartis, Schwartz Pharma, Newron Pharmaceuticals and Takeda/Nycomed. In his last position he was involved in the acquisition of Nycomed by Takeda and drove the plan for the new integrated Global Licensing and Business Development structure as member of the Integration Team.

About to-BBB
to-BBB is a clinical stage biotechnology company developing novel treatments for devastating brain disorders, such as brain cancer and neuroinflammatory diseases. The Company combines existing drugs with to-BBB’s proprietary G-Technology® for enhanced drug delivery across the blood-brain barrier. This platform technology combines the widely used drug delivery approach of pegylated liposomes with the endogenous tripeptide glutathione as targeting ligand in a novel and safe way. to-BBB’s lead product 2B3-101 is investigated in a Phase IIa trial for the treatment of primary brain tumors as well as brain metastases. to-BBB’s second product 2B3-201 for MS relapses and other neuroinflammatory diseases will enter into a Phase I clinical study by the end of 2013. 

to-BBB is headquartered in the Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan. Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM).

 
Corporate Contacts:

Willem van Weperen, MSc, MBA

Chief Executive Officer

to-BBB technologies BV

Phone: +31 71 33 222 51

E-mail: WillemVanWeperen@toBBB.com

Sijme Zeilemaker, MSc

Business Development Manager

to-BBB technologies BV

Phone: +31 71 3322256

E-mail: SijmeZeilemaker@toBBB.com 

to-BBB technologies BV

J.H. Oortweg 19

2333 CH Leiden

Leiden Bio Science Park

The Netherlands

Source: to-BBB
2.0
2.0 from 11 votes
Free Newsletter
Trending News
Related Videos